PEG

Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
SAN, MHC class I, PFS, Forward-looking statement, Nektar, Merck Group, Histocompatibility, U.S. Securities and Exchange Commission, Patent, Multiple myeloma, Overalls, Squamous cell carcinoma, Annual general meeting, Immunotherapy, Research, Risk, Merck, UC, Colorectal cancer, Development, Population, MHC, COVID-19, Therapy, Heparin, Failure, PD-L1, Limited partnership, Avelumab, Antibody, Safety, PD-1, Infection, Survival, SITC, Senior, Immunology, Neoplasm, Program, PEG, Clinical trial, Maintenance, Cell, B-cell lymphoma, Society for Immunotherapy of Cancer, NK, Nektar Therapeutics, Patient, Treatment, Memory, NKTR, Pfizer, Security (finance), Trial, PD, Trial of the century, Palladium, Pharmaceutical industry, Vaccine, Cancer

SAN FRANCISCO, Nov. 10, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • NKTR-288 is a novel polyethylene glycol (PEG)-conjugate of interferon gamma (IFN-), designed to modify binding of IFN- to its substrates and optimize the duration of IFN- signaling.
  • These data support further evaluation of NKTR-288 as a monotherapy or in combination with checkpoint inhibitors in the clinical setting.
  • It highlights the potential of NKTR-288 to augment currently available PD-1 or PD-L1 treatment strategies and possibly broaden the responsive patient population."
  • Key details and takeaways from the presentation are as follows:
    Abstract 1086: "NKTR-288, a PEGylated Interferon Gamma Drug Candidate for the Treatment of Cancer", Hamel, D., et al.

ICE to Launch European LNG Futures for North-West and South-West Europe and Three Supporting French, German and Italian Natural Gas Futures

Retrieved on: 
Thursday, October 27, 2022
Finance, Oil, Gas, Banking, Energy, Professional Services, Carbon, Technology, New, NYSE, NBP, Private Securities Litigation Reform Act, Agency for the Cooperation of Energy Regulators, ACER, Annual report, Intercontinental Exchange, JKM, PSV, Coal, KIDS, EU, PEG, New York Stock Exchange, U.S. Securities and Exchange Commission, Mission statement, Cyprus Securities and Exchange Commission, Prandtl number, ICE, Risk, Council of European Energy Regulators, SEC, WIM, Strategic autonomy, Contract, Henry Hub, Intercontinental, THE, USD, Risk management, Natural gas, TTF, Security (finance), Oil, LNG, Electricity

Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology, and market infrastructure, today announced plans to launch two liquid natural gas (LNG) futures contracts for North-West Europe and South-West Europe.

Key Points: 
  • Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology, and market infrastructure, today announced plans to launch two liquid natural gas (LNG) futures contracts for North-West Europe and South-West Europe.
  • The price of natural gas in Europe remains high because of an imbalance between supply and demand, caused by the significant reduction in the supply of natural gas into Europe from Russia and the downstream impact of physical capacity constraints across the European natural gas network.
  • Additionally, ICE plans to launch three supporting French PEG, German THE and Italian PSV Natural Gas 1st Line contracts on December 5, subject to regulatory approval.
  • Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange.

Bright Peak Therapeutics to Present Innovative Best-in-Class and Multifunctional Regulatory T Cell (Treg) Enhancers at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments

Retrieved on: 
Thursday, October 20, 2022
Peripheral tolerance, SAN, CA, Regulatory T cell, Therapy, Conference, IND, Autoimmune disease, Cytokine, Degenerative disease, Patient, Biotechnology, Tissue, PEGylation, International Conference on Environmental Systems, Technology, Cancer, Mouse, KDA, PEG, Autoimmunity, 2021 Essex County Council election, GLOBE, Huangshan, IL-2, Vaccine, Fine chemical

SAN DIEGO and BASEL, Switzerland, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a privately held biotechnology company developing next-generation multifunctional precision immunotherapies, today announced the presentation of two posters showcasing the potential of its unique chemical protein engineering platform at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments taking place October 20-25, 2022, in Chania, Crete.

Key Points: 
  • Tregs are essential for maintaining peripheral tolerance, preventing autoimmunity and limiting chronic inflammatory diseases.
  • IL-2 is an essential cytokine critical for Treg activation and proliferation, and low-dose IL-2 has demonstrated promising preliminary clinical efficacy in several autoimmune diseases.
  • Abstract Highlights: Bright Peak has developed a cell-free chemical protein synthesis and conjugation platform to rapidly generate optimized antibody-cytokine (immunocytokine, IC) therapeutics within weeks.
  • This suggests that TNF-IL2 IC may exhibit higher local activity in inflamed tissues where TNF is present at high levels.

PEG Companies Acquires 40-Acre Site in Caldwell for Large Build-for-Rent Development

Retrieved on: 
Thursday, October 13, 2022
Thought, Growth, Population, Housing, Love, Company, AUM, Spring Run, PEG, College, GLOBE, City, BFR, Freedom, Real estate, Public relations, Investment

"We commend Caldwell leaders for their forward thinking and strategic efforts to bring a diverse range of quality housing options to their community," said David Bourne, Director of Investments at PEG.

Key Points: 
  • "We commend Caldwell leaders for their forward thinking and strategic efforts to bring a diverse range of quality housing options to their community," said David Bourne, Director of Investments at PEG.
  • "We are pleased to support this exciting project within the fast-growing east Caldwell region," said Steven Jenkins, Economic Development Director for the City of Caldwell.
  • PEG Property Group, the property management arm of PEG that will operate the project, anticipates welcoming the first Alante residents to their homes in early 2024.
  • PEG Companies [PEG] is a full-service commercial real estate investment firm, known for its unique approach to creating value.

Kaufman & Broad SA: capital increase offer reserved for employees 'KB Shares 2022'

Retrieved on: 
Wednesday, October 12, 2022
Regulatory News Service, PEG, ISIN, Security (finance)

On the 15th of June 2022, Kaufman & Broad SA announced the launch of the KB Shares 2022 leveraged offer, comprising a guarantee of investment, reserved to the group employees members of the Group Savings Plan (PEG).

Key Points: 
  • On the 15th of June 2022, Kaufman & Broad SA announced the launch of the KB Shares 2022 leveraged offer, comprising a guarantee of investment, reserved to the group employees members of the Group Savings Plan (PEG).
  • At the date of publication, Kaufman & Broad SA acknowledges the completion of the capital increase resulting from the subscriptions to the KB Shares 2022 offer.
  • This operation strengthens the employees position of one of largest shareholders of Kaufman & Broad SA expressing their commitment and confidence in their company.
  • The 299,999 new shares issued in this offer are ordinary shares, entirely assimilated to the existing shares and carry current dividend entitlement.

PSEG To Announce Third-Quarter 2022 Financial Results On Oct. 31

Retrieved on: 
Wednesday, October 12, 2022
Zero, U.S. Securities and Exchange Commission, Investor relations, SEC, ESG, Private Securities Litigation Reform Act, U.N, NYSE, Annual report, Public Service Enterprise Group, Security (finance), Dow Jones, PEG, Long Island Power Authority, PSE, Gas, Forward-looking statement, Bloomberg, PSEG

NEWARK, N.J., Oct. 12, 2022 /PRNewswire/ -- Public Service Enterprise Group Incorporated (PSEG) will host its third-quarter 2022 earnings call at 11:00 a.m.

Key Points: 
  • NEWARK, N.J., Oct. 12, 2022 /PRNewswire/ -- Public Service Enterprise Group Incorporated (PSEG) will host its third-quarter 2022 earnings call at 11:00 a.m.
  • ET on Monday, Oct. 31, during which management will discuss third-quarter financial results and other important matters.
  • PSEG's businesses include Public Service Electric and Gas Co. (PSE&G), PSEG Power and PSEG Long Island.
  • From time to time, PSEG and PSE&G release important information via postings on their corporate Investor Relations website at https://investor.pseg.com .

Ralph LaRossa Honored by American Gas Association

Retrieved on: 
Monday, October 10, 2022
Diamond, Zero, LinkedIn, AGA, Veteran, Population, Conference, Natural gas, ESG, U.N, NYSE, Public Service Enterprise Group, Carbon, Distinguished Service Award, Workforce, Industry, Dow Jones, Emergency, PEG, Long Island Power Authority, PSE, Safety, Gas, MetLife Stadium, Climate change, Hydrogen, Dick LaRossa, Bloomberg, Methane, Solution, PSEG, Leadership, Renewable energy, Management

NEWARK, N.J., Oct. 10, 2022 /PRNewswire/ -- The AGA has announced that PSEG President and CEO Ralph LaRossa has received their 2022 Distinguished Service Award, presented today during the AGA Executive Conference. The honor recognizes visionary leaders who enhance customers' lives through dedication to their industry and communities.

Key Points: 
  • "Having started my career in natural gas and having served as an AGA president, I couldn't be more honored to receive this award," LaRossa remarked.
  • Americans rely on natural gas because it has proven to be safe and affordable.
  • LaRossa championed workforce and skills development and inspired others in the gas industry to better prepare employees to deliver energy to the customers of tomorrow.
  • LaRossa advocated for New Jersey's Gas System Modernization Program to upgrade more than 1,400 miles of cast-iron and steel pipes and install flood-proofed metering and regulating stations.

ProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic

Retrieved on: 
Friday, October 7, 2022
SAN, CA, ATM, PARP, Mayo Clinic, Clinical professor, Neoplasm, Woman, Mayo, Patient, Biotechnology, Carboplatin, RAD51, Hendrickson, DRS, Pharmacokinetics, PEG, Safety, Recurrence, Protein, GLOBE, Clinical trial, SLFN11, Death, Peptide, SN-38, Ovarian cancer, Biomarker, Pharmaceutical industry, Medical imaging, Irinotecan

SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian cancer at the Mayo Clinic.

Key Points: 
  • SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian cancer at the Mayo Clinic.
  • Carboplatin responses become shorter with each recurrence, and in platinum-resistant ovarian cancer the response rate to subsequent agents is only 15- to 20%.
  • Previous studies have shown that conventional inhibitors of the enzyme topoisomerase 1 have clinical activity in platinum-resistant ovarian cancer, and the Mayo trial seeks to improve this activity with the new PLX038.
  • Added ProLynx co-founder and President Daniel V. Santi Conventional short-acting topoisomerase 1 inhibitors have clinical activity in platinum-resistant ovarian cancer.

Richard L. Mayo II Joins CAN TV as Chief of External Affairs

Retrieved on: 
Tuesday, September 20, 2022
Nielsen, McCormick Theological Seminary, Communication, Culture, PEG, Politics, Chicago Access Network Television, News, Partnership, Mayo, CAN TV, Government, McCormick, Marketing communications, Foreign policy, Interview, GLOBE, Marketing, Education, Television

CHICAGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Chicago Access Network Television (CAN TV) has announced the appointment of Richard L. Mayo II as Chief of External Affairs.

Key Points: 
  • CHICAGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Chicago Access Network Television (CAN TV) has announced the appointment of Richard L. Mayo II as Chief of External Affairs.
  • Mayo will join CAN TV after serving most recently as Senior Director of Marketing & Communications at McCormick Theological Seminary.
  • Richard will help reintroduce CAN TV to our long-time fans and ensure more Chicagoans know about this unique local resource."
  • Mayo is excited about the opportunity and ready to continue to build on the great work, and legacy, of CAN TV.

Hardman & Co Research on Oakley Capital Investments Ltd (OCI): 1H’22: results prove NAV real, resilient and growing

Retrieved on: 
Tuesday, September 20, 2022
PEG, EV, PE, EBITDA, NAV, Oakley, Growth, OCI, Re Recher's Will Trusts, Disclosure, Renewable energy

Hardman & Co Research on Oakley Capital Investments Ltd (OCI): 1H22: results prove NAV real, resilient and growing

Key Points: 
  • Hardman & Co Research on Oakley Capital Investments Ltd (OCI): 1H22: results prove NAV real, resilient and growing
    We believe a significant driver to the whole listed PE sector trading at a large discount to NAV is investors concerns about whether the NAVs are real and conservative, and whether they can grow.
  • For OCI, the detail in its latest results disclosure should, once again, abate any of those worries.
  • Oakley adds value to companies in all economic environments, especially uncertain ones.
  • Please click on the link below for the full report:
    If you are interested in meeting the company, you can register your interest by clicking on the above link